

Express Mail No.: EV 654 850 846 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	James F. Young <i>et al.</i>	Confirmation No.:	7010
Serial No.:	09/724,531	Art Unit:	1648
Filed:	November 28, 2000	Examiner:	CHEN, Stacy Brown
For:	METHODS OF ADMINISTERING/DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT	Attorney Docket No.:	10271-021-999 CAM:209073-999020

**TERMINAL DISCLAIMER**

MAIL STOP ~~AT~~ RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Your Petitioner, William C. Bertand, Jr. represents that s/he holds the position of Vice President, General Counsel of MedImmune, Inc., the assignee of the entire 100% right, title and interest in and to the above identified application by virtue of a chain of title from the inventors of the above-identified application to the current assignee as shown below. Copies of the assignments in the chain of title, as indicated below, are attached hereto as **Exhibit A**.

1. From James Young, Scott Koenig, and Leslie Johnson to MedImmune, Inc., recorded in the United States Patent and Trademark Office on March 21, 2001, at Reel/Frame 011688/0233;
2. From Jeffry Watkins and William Huse to Applied Molecular Evolution, Inc., copy attached;
3. From Herren Wu to Applied Molecular Evolution, Inc., copy attached; and
4. From Applied Molecular Evolution, Inc. to MedImmune, Inc., copy attached.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of either U.S. Patent No. 6,656,467, which issued on December 3, 2003, or U.S. Patent No. 6,818,216, which issued on November 16, 2004, and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent Nos. 6,656,467 and 6,818,216.

Petitioner further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of U.S. Patent Nos. 6,656,467 and 6,818,216 in the event that either of said patents later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Petitioner hereby confirms that s/he has reviewed the assignments in the chain of title and, to the best of his/her knowledge and belief, title is in the assignee seeking to take action in this matter and that s/he is empowered to act on behalf of **MedImmune, Inc.**

Petitioner hereby declares that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 27th day of September, 2005.

**MedImmune, Inc.**

By: \_\_\_\_\_



Name: William C. Beahm, Jr.

Position: Vice President, General Counsel